Medexus Pharmaceuticals (TSE:MDP) Stock Rating Upgraded by Raymond James

Medexus Pharmaceuticals (TSE:MDP) was upgraded by analysts at Raymond James from a “market perform” rating to an “outperform” rating in a report issued on Wednesday, Marketbeat Ratings reports. The brokerage currently has a C$4.00 price target on the stock, up from their prior price target of C$3.00. Raymond James’ target price indicates a potential upside of 87.79% from the company’s previous close. Raymond James also issued estimates for Medexus Pharmaceuticals’ FY2029 earnings at $0.89 EPS.

Other equities analysts have also recently issued research reports about the company. Stifel Nicolaus lifted their price target on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Stifel Canada raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Monday, August 12th. Finally, Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of C$5.25.

Medexus Pharmaceuticals Stock Down 0.9 %

TSE:MDP opened at C$2.13 on Wednesday. The business has a 50 day moving average price of C$2.47 and a two-hundred day moving average price of C$2.19. The company has a market cap of C$52.25 million, a P/E ratio of 43.20 and a beta of 1.96. Medexus Pharmaceuticals has a twelve month low of C$1.44 and a twelve month high of C$3.16.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.